These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 28135142)

  • 1. How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?
    Loibl S; Denkert C
    J Clin Oncol; 2017 Apr; 35(10):1029-1030. PubMed ID: 28135142
    [No Abstract]   [Full Text] [Related]  

  • 2. Biomarkers of residual disease after neoadjuvant therapy for breast cancer.
    Penault-Llorca F; Radosevic-Robin N
    Nat Rev Clin Oncol; 2016 Aug; 13(8):487-503. PubMed ID: 26856744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast Cancer.
    Prowell TM; Beaver JA; Pazdur R
    N Engl J Med; 2019 Feb; 380(7):612-615. PubMed ID: 30763188
    [No Abstract]   [Full Text] [Related]  

  • 4. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
    Villegas SL; Darb-Esfahani S; von Minckwitz G; Huober J; Weber K; Marmé F; Furlanetto J; Schem C; Pfitzner BM; Lederer B; Engels K; Kümmel S; Müller V; Mehta K; Denkert C; Loibl S
    Breast Cancer Res Treat; 2018 Feb; 168(1):179-187. PubMed ID: 29177689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.
    Enomoto Y; Morimoto T; Nishimukai A; Higuchi T; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Nomura T; Takeda M; Watanabe T; Hirota S; Miyoshi Y
    Int J Clin Oncol; 2016 Apr; 21(2):254-261. PubMed ID: 26338270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer.
    Cockburn A; Yan J; Rahardja D; Euhus D; Peng Y; Fang Y; Rumnong Sarode V
    Hum Pathol; 2014 Feb; 45(2):249-58. PubMed ID: 24289969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and clinical impact of residual disease after neoadjuvant chemotherapy.
    Viale G
    Breast; 2013 Aug; 22 Suppl 2():S88-91. PubMed ID: 24074800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
    Tinari N; Lattanzio R; Natoli C; Cianchetti E; Angelucci D; Ricevuto E; Ficorella C; Marchetti P; Alberti S; Piantelli M; Iacobelli S
    Clin Cancer Res; 2006 Mar; 12(5):1501-6. PubMed ID: 16533774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Japanese Breast Cancer Society Clinical Practice Guideline for pathological diagnosis of breast cancer.
    Horii R; Honma N; Ogiya A; Kozuka Y; Fukuda T; Yoshida M; Ohsumi S; Mukai H;
    Breast Cancer; 2015 Jan; 22(1):59-65. PubMed ID: 25022266
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessment of Residual Disease With Molecular Breast Imaging in Patients Undergoing Neoadjuvant Therapy: Association With Molecular Subtypes.
    Menes TS; Golan O; Vainer G; Lerman H; Schneebaum S; Klausner J; Even-Sapir E
    Clin Breast Cancer; 2016 Oct; 16(5):389-395. PubMed ID: 27282845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size.
    Kim YS; Chang JM; Moon HG; Lee J; Shin SU; Moon WK
    Ann Surg Oncol; 2016 Apr; 23(4):1135-42. PubMed ID: 26628432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer: comparison of the accuracies of mammography and MRI in predicting pathological residual tumor.
    An YY; Kim SH; Kang BJ
    World J Surg Oncol; 2017 Nov; 15(1):198. PubMed ID: 29110671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Therapy for HER2-positive Breast Cancer.
    Wuerstlein R; Harbeck N
    Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neoadjuvant treatment in human epidermal growth factor receptor 2-positive breast cancer].
    Liu Y; Liu S; Zhang H; Xu L; Li T; Duan X
    Zhonghua Wai Ke Za Zhi; 2015 Dec; 53(12):901-4. PubMed ID: 26850663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease.
    Klintman M; Buus R; Cheang MC; Sheri A; Smith IE; Dowsett M
    Clin Cancer Res; 2016 May; 22(10):2405-16. PubMed ID: 27179111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical usefulness and relevance of intermediate endpoints for cytotoxic neoadjuvant therapy.
    Fontanella C; Loibl S; von Minckwitz G
    Breast; 2015 Nov; 24 Suppl 2():S84-7. PubMed ID: 26279131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox.
    Mehta RS
    J Clin Oncol; 2008 Jul; 26(19):3286-8; author reply 3288. PubMed ID: 18591566
    [No Abstract]   [Full Text] [Related]  

  • 20. Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
    van Dam PA; van Dam VC; Altintas S; Papadimitriou K; Rolfo C; Trinh XB
    Eur J Surg Oncol; 2016 Mar; 42(3):333-42. PubMed ID: 26776766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.